Page 946«..1020..945946947948..960970..»

Category Archives: Transhuman News

Causal’ Blood Pressure Genes Found in the Human Kidney – The FINANCIAL

Posted: May 11, 2021 at 10:53 pm

The FINANCIAL -- An international team of scientists led by The University of Manchester have discovered 179 kidney genes responsible for high blood pressure.High blood pressure, known as silent killer, is one of the most common human diseases and remains the key risk factor for strokes and heart attacks.

According to The University of Manchester, high blood pressure - or hypertension- runs in families but the exact mechanisms through which genes influence individuals predisposition to hypertension is not clear.

The discoveries published in Nature Genetics, one of the worlds leading journals, shed new light on our understanding of genetic predisposition to high blood pressure.

The study, supported primarily by the British Heart Foundation and Kidney Research UK, was possible through access to huge datasets of human DNA and RNA from possibly the worlds largest repository of human kidney tissue-based omics.

The team led by Professor Maciej Tomaszewski at The University of Manchester characterised how information inherited in DNA translates into genetic predisposition to high blood through changes in activity of certain kidney genes.

These studies included comprehensive analyses conducted at various molecular levels of kidney tissue combining together DNA, RNA and other layers from the same set of kidney tissue samples.

They also used a statistical method - called Mendelian randomisation to screen for evidence of causal associations between thousands of variables and millions of genetic variants using the high-performance computing resources hosted at the University of Manchester.

Around 80 per cent of 179 genes discovered by the team have never before been associated with high blood pressure before. Some of these genes can be targeted by existing medicines creating new opportunities to treat high blood pressure, The University of Manchester notes.

Principal Investigator Maciej Tomaszewski, Professor of Cardiovascular Medicine and University of Manchester and a Consultant Physician said: Hypertension is a key driver of coronary heart disease and stroke and the single most important cause of disability and premature death worldwide.

Yet, our understanding of the role of genes in development of this condition has been incomplete.

Professor Tomaszewski is also a member of Manchester Academic Health Science Centre (MAHSC), a partnership between academia and NHS organisations in Greater Manchester to drive health research, improve health education and transform patient care.

Professor Fadi J Charchar, a senior author from Federation University, added: Our studies filled an important gap in our knowledge through uncovering new genetic variants, kidney genes, molecular mechanisms and biological pathways of key relevance to genetic regulation of blood pressure and inherited susceptibility to hypertension.

Professor Andrew Morris, from The University of Manchester, commented: Through our unparalleled access to the kidney tissue resource, we provide evidence for the role of the kidney as the mediator of common genetic effects on blood pressure and a potentially causal role of blood pressure in the development of renal disease.

First author: Dr James Eales from The University of Manchester said: By explaining the molecular mechanisms of hypertension embedded in the kidney, our study will ultimately lead to advancements in patient-centred diagnostic accuracy in hypertension.

It will also lead to new targeted strategies to lowering blood pressure, thereby accelerating progress in precision medicine.

Professor Tomasz Guzik, from the University of Glasgow, said: These exciting discoveries uncover a range of new possible mechanisms of hypertension some related to blood vessels, kidneys but also body immune defences and pave the way for the development of novel genetic therapies for blood pressure.

Professor James Leiper, Associate Medical Director at the BHF said: We have known for many years that the kidney is a major regulator of blood pressure, but our understanding of precisely how the kidney controls blood pressure is incomplete.

The identification of this large set of genes that appear to directly affect blood pressure fills in an important missing piece of that puzzle. The researchers have also found a subset of these genes that are a potential new target for the treatment of hypertension.

This is important because many people taking existing medications still struggle to control their blood pressure. If doctors have more tools to work with then it will help stop thousands of lives being lost each year from this potentially preventable condition.

Professor Jeremy Hughes, kidney doctor and chair of trustees at Kidney Research UK said: "High blood pressure is both a cause and consequence of kidney disease and we need better treatments to protect patients from harm such as strokes and heart attacks.

This innovative study harnesses the power of a kidney tissue biobank and state-of-the-art genetic analysis to identify novel genes that link the kidney to high blood pressure. We hope this new knowledge will eventually lead to new treatments that benefit kidney patients."

See the article here:
Causal' Blood Pressure Genes Found in the Human Kidney - The FINANCIAL

Posted in Human Genetics | Comments Off on Causal’ Blood Pressure Genes Found in the Human Kidney – The FINANCIAL

Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy…

Posted: at 10:53 pm

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice

- Multiple analyses demonstrate in vitro transduction with dual AK-OTOF vector results in full-length otoferlin expression, with no detection of truncated proteins

- Long-term, local expression of anti-VEGF protein is robust and well tolerated following intracochlear administration of AK-antiVEGF in non-human primates

- Akouos continues to progress towards planned IND submissions for AK-OTOF in the first half of 2022 and for AK-antiVEGF in 2022

BOSTON, May 11, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today presented nonclinical data supporting the future clinical development of both AK-OTOF, a gene therapy intended for the treatment of otoferlin gene (OTOF)-mediated hearing loss, and AK-antiVEGF, a gene therapy intended for the treatment of vestibular schwannoma, in three digital presentation sessions at the virtual American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting.

We are excited to share new data that highlight the potential of genetic medicines for inner ear conditions with the broader gene therapy community, said Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos. Inner ear conditions represent one of the largest areas of unmet need in medicine today, and one of the challenges in this area is the ability to efficiently address the broad range of conditions that collectively affect hundreds of millions of individuals worldwide. The nonclinical data presented today for the AK-OTOF and AK-antiVEGF programs demonstrate how we are leveraging our genetic medicines platform and multiple AAV-mediated modalities, including gene transfer and therapeutic protein expression, to begin to address that challenge.

Nonclinical data presented at ASGCT for AK-OTOF continue to support the potential to restore physiologic hearing and provide long-lasting benefit to individuals with OTOF-mediated hearing loss. In Otof knockout mice, AK-OTOF administration results in durable expression of human otoferlin protein sufficient for sustained restoration of auditory function. In addition, data presented indicate that expression of exogenous secreted protein at or above reported biologically active levels, driven by a ubiquitous promoter, is well tolerated in non-human primates following administration of AK-antiVEGF. These IND-enabling nonclinical studies are promising and support future clinical development. Our team continues to work towards submission of INDs for AK-OTOF and AK-antiVEGF expected in 2022, said Greg Robinson, Ph.D., chief scientific officer of Akouos.

In Vitro and In Vivo Analyses of Dual Vector Otoferlin Expression to Support the Clinical Development of AK-OTOF (AAVAnc80-hOTOF Vector)

Presenting Author: Eva Andres-Mateos

Abstract Number: 355

Otoferlin plays a critical role in exocytosis of synaptic vesicles at the inner hair cell synapse, and mutations inOTOF, the gene encoding otoferlin, are associated with autosomal recessive sensorineural hearing loss. AK-OTOF is designed to deliver normal OTOF by utilizing a dual vector approach,which encodes the 5 and the 3 components of OTOF. Multiple analyses demonstrate in vitro transduction with dual AK-OTOF vector results in full-length human otoferlin (RNA and protein), with no detection of truncated proteins from either AK-OTOF or its component vectors (5hOTOF and 3hOTOF). A one-to-one ratio of the AK-OTOF component vectors appears to be optimal for efficient reconstitution of full-length human otoferlin. In cynomolgus macaques, full-length human otoferlin protein expression is detected in inner hair cells of non-human primate (NHP) cochleae by both immunohistochemistry and immunodetection one month following intracochlear administration of AAVAnc80-FLAG.hOTOF.

The digital presentation is located at https://akouos.com/gene-therapy-resources/.

Durable Recovery of Auditory Function Following Intracochlear Delivery of AK-OTOF (AAVAnc80-hOTOF Vector) in a Translationally Relevant Mouse Model of Otoferlin Gene (OTOF)-Mediated Hearing Loss

Presenting Author: Ann Hickox

Abstract Number: 569

Otoferlin gene (OTOF)-mediated hearing loss is caused by mutations in the OTOF gene and is typically characterized by a congenital, Severe to Profound sensorineural hearing loss. The physiologic deficiency resulting from OTOF mutations is localized; specifically, synaptic transmission between the inner hair cell and the auditory nerve is affected, as measured by an absent or abnormal auditory brain stem response (ABR). Gene therapy for OTOF-mediated hearing loss is expected to confer the greatest benefit when cochlear integrity is preserved, as represented by present otoacoustic emissions (OAEs). Individuals with OTOF-mediated hearing loss typically experience a decline in cochlear integrity within the first decade of life, indicated by initially present, then absent, OAEs. In an Otof knockout mouse model that recapitulates the human phenotype, administration of AK-OTOF, an adeno-associated viral gene therapy vector encoding human otoferlin under the control of a ubiquitous promoter, results in durable restoration of auditory function, as measured by ABRs, and may preserve OAEs.

The digital presentation is located at https://akouos.com/gene-therapy-resources/.

Demonstration of Tolerability of a Novel Delivery Approach and Secreted Protein Expression Following Intracochlear Delivery of AK-antiVEGF (AAVAnc80-antiVEGF Vector) in Non-Human Primates

Presenting Author: John Connelly

Abstract Number: 358

Data published from previous clinical trialsshow that systemic VEGF inhibitor therapy can reduce vestibular schwannoma (VS) tumor volume and improve hearing in some participants with mutations in the NF2 gene. However, toxicity limits the potential of this systemic delivery approach from being a viable treatment option for vestibular schwannoma. The exposure and tolerability of local expression of anti-VEGF protein following bilateral, intracochlear administration of AK-antiVEGF was evaluated through analyses of protein levels, as well as physiologic and histologic evaluations, in NHPs. Long-term, local expression of anti-VEGF protein, driven by a ubiquitous promoter, is robust and well tolerated in NHPs following intracochlear administration of AK-antiVEGF. Computational modelling supports the potential for diffusion of anti-VEGF protein at or above reported biologically active levels to the site of the VS tumor.

The digital presentation is located at https://akouos.com/gene-therapy-resources/.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, plans, and timing of our future clinical trials and our research and development programs, the timing of our IND submissions for AK-OTOF and AK-antiVEGF, our expectations regarding our manufacturing capabilities and timelines, and the period over which we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: our limited operating history; uncertainties inherent in the development of product candidates, including the initiation and completion of nonclinical studies and clinical trials; whether results from nonclinical studies will be predictive of results or success of clinical trials; the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for, our product candidates; our expectations regarding our regulatory strategy; our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and marketable securities; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential addressable patient population for our product candidates; our commercialization, marketing, and manufacturing capabilities and strategy; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to identify additional products, product candidates, or technologies with significant commercial potential that are consistent with our commercial objectives; the impact of government laws and regulations; risks related to competitive programs; the potential that our internal manufacturing capabilities and/or external manufacturing supply may experience delays; the impact of the COVID-19 pandemic on our business, results of operations, and financial condition; our ability to maintain and establish collaborations or obtain additional funding; and other factors discussed in the Risk Factors included in the Companys Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission, and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Media:Katie Engleman, 1ABkatie@1abmedia.com

Investors:Courtney Turiano, Stern Investor Relations Courtney.Turiano@sternir.com

See the article here:
Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy...

Posted in Human Genetics | Comments Off on Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy…

Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID – BioSpace

Posted: at 10:53 pm

BOSTON and LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced data published in the New England Journal of Medicine (NEJM) evaluating the safety and efficacy of investigational gene therapy products, including OTL-101, for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). Fifty (50) ADA-SCID patients were treated with investigational gene therapy composed of autologous CD34+ hematopoietic stem cells (HSCs) transduced ex vivo with a self-inactivating lentiviral vector (LVV) encoding the human ADA gene. Results showed 100% overall survival and 95% event-free survival (defined as survival in the absence of enzyme replacement therapy reinstitution or rescue allogeneic hematopoietic stem cell transplant (HSCT)) at two and three years.

The data were taken from three Phase 1/2 clinical studies (n=40), two conducted in the U.S. and one in the UK, as well as from a compassionate use program (n=10) in the UK. Results also showed sustained ADA gene expression, metabolic correction, and functional immune reconstitution in 48 out of the 50 patients. Discontinuation of immunoglobulin replacement therapy (IgRT) was seen in 26 out of 29 U.S. study patients (90%) who demonstrated sustained engraftment by two years and 19 out of 19 UK study patients (100%) who had sustained engraftment by three years. Additionally, no deaths, monoclonal expansion events, leukoproliferative complications, or emergence of replication-competent lentivirus were observed.

Results from a one-time treatment with experimental lentiviral HSC gene therapy for ADA-SCID are compelling, most notably the overall and event-free survival rates (100% and 95%, respectively) observed at two and three years post-treatment, said Donald Kohn, M.D., distinguished professor of Microbiology, Immunology & Molecular Genetics and Pediatrics at the University of California, Los Angeles (UCLA), member of the UCLA Broad Stem Cell Research Center, director of the UCLA Human Gene and Cell Therapy Program, and co-lead author of the NEJM paper. We saw no reports of graft versus host disease, and the ability to discontinue immunoglobulin replacement therapy over time in most patients is also notable for the gene therapy, contributing to its overall benefit-risk profile as a potential treatment for ADA-SCID.

ADA-SCID is a rare and life-threatening primary immunodeficiency caused by a genetic mutation that affects white blood cell production. Patients with ADA-SCID suffer from frequent, severe infections as well as non-immune symptoms including those affecting the gastrointestinal, skeletal and nervous systems. Without treatment, children born with ADA-SCID typically pass away by 2 years of age.

With sustained engraftment of up to three years, these data show the potential of HSC gene therapy to correct the underlying genetic cause of ADA-SCID, delivering positive outcomes in a single treatment, said Bobby Gaspar, M.D., Ph.D., chief executive officer of Orchard Therapeutics. We are encouraged by the results weve seen across this large dataset of 50 treated patients, and believe they reinforce the promise of the HSC gene therapy approach for treating and potentially curing certain life-threatening genetic diseases.

Results of Phase 1/2 Clinical Studies for ex vivo LVV HSC Gene Therapy

Fifty patients with ADA-SCID were treated with an investigational gene therapy composed of autologous CD34+ HSCs transduced ex vivo with a self-inactivating LVV encoding the human ADA gene. Thirty (30) subjects enrolled in the U.S. studies received OTL-101 as part of the registrational trials, which were conducted at the University of California, Los Angeles (UCLA), and the National Institutes of Health (NIH). Study patients in the UK received a very similar investigational HSC gene therapy product based on the same ADA LVV. An analysis was conducted to assess the safety and efficacy of the gene therapy for the treatment of ADA-SCID, which integrated two prospective, nonrandomized, Phase 1/2 clinical studies in the U.S. (using fresh and cryopreserved formulations) at two years follow-up, alongside a prospective, nonrandomized Phase 1/2 clinical study conducted in the UK (fresh formulation) and compassionate use patients treated with the same UK protocol with three years follow-up, used as supportive evidence.

Efficacy Data

Results published in NEJM from all 50 patients treated across the studies showed:

Results were comparable in U.S. study patients receiving the fresh formulation with those receiving the cryopreserved formulation as shown by median VCN in granulocytes and PBMCs, median CD3+ T-cell levels, and median ADA activity.

Safety Data

Across all patients, no deaths, events of monoclonal expansion, leukoproliferative complications, or emergence of replication-competent lentivirus were noted. Adverse events were reported in all patients, most of which were mild or moderate and considered related to conditioning. No autoimmune or graft versus host (GvHD) events were noted.

Two U.S. study patients and two UK study patients had serious adverse events of immune reconstitution inflammatory syndrome (IRIS), beginning approximately 3 and 14 months and 3 and 22 months post-infusion, respectively. These events were considered unrelated to gene therapy, resolved with supportive therapy and were linked to transitory immune dysregulation during immune reconstitution.

About ADA-SCID and OTL-101

ADA-SCID is a rare, life-threatening, inherited disease of the immune system caused by mutations in the ADA gene resulting in a lack of, or minimal, immune system development.1-4 The first symptoms of ADA-SCID typically manifest during infancy with recurrent severe bacterial, viral and fungal infections and overall failure to thrive, and without treatment the condition can be fatal within the first two years of life. The incidence of ADA-SCID is currently estimated to be one in 500,000 live births in the United States and between one in 200,000 and one in 1 million in Europe.3 OTL-101 is an investigational autologous ex vivo lentiviral hematopoietic stem cell-based gene therapy for the treatment of patients diagnosed with ADA-SCID. The registrational trials for OTL-101 recently concluded and were conducted at the University of California, Los Angeles (UCLA) and the National Institutes of Health (NIH). Orchard has worldwide rights to the OTL-101 program through license agreements with University of California, Los Angeles (UCLA), and UCL Business, Ltd. OTL-101 has received orphan drug designation from the FDA and the EMA for the treatment of ADA-SCID and Breakthrough Therapy Designation from the FDA. OTL-101 has also received a Rare Pediatric Disease Designation from the FDA.

The research was funded by Orchard Therapeutics with support from the National Institute of Allergy and Infectious Diseases, the National Heart, Lung and Blood Institute, and the National Human Genome Research Institute (all part of the U.S. National Institutes of Health); the California Institute for Regenerative Medicine; the U.K. National Institute for Health Researchs Biomedical Research Centre at Great Ormond Street Hospital for Children National Health Service Foundation Trust and University College London.

About Orchard Therapeutics

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, and the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates, will be insufficient to support regulatory submissions or marketing approval in the US or EU, as applicable, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchards ability to commercialize its product candidates, if approved, or Libmeldy in the EU; the risk that the market opportunity for Libmeldy, or any of Orchards product candidates, may be lower than estimated; and the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaBenjamin NavonDirector, Corporate Communications+1 857-248-9454Benjamin.Navon@orchard-tx.com

1Orphanet. SCID due to ADA deficiency. 2Whitmore KV, Gaspar HB. Front Immunol. 2016;7:314. 3Kwan A, et al. JAMA. 2014;312:729-738. 4Sauer AV, et al. Front Immunol. 2012;3:265.

Original post:
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID - BioSpace

Posted in Human Genetics | Comments Off on Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID – BioSpace

Influential Voices On The Future Of Work: Brian David Johnson, Futurist – Forbes

Posted: at 10:50 pm

Brain David Johnson - Futurist

Each month I feature different leaders' voices offering insights into the future of work and changes theyve seen within their industry since the pandemic. Im particularly interested in leaders that approach challenges as opportunities to create positive and lucrative business opportunities. This column profiles everyone from celebrities and business people, to community leaders and changemakers, and gives readers a peek behind the veil of different businesses and industries.

This month I interviewed Brian David Johnson (BDJ), who is a futurist, author and professor. BDJ lives, eats and breathes the future. The slightest scratch on the surface of what BDJ does will uncover a plethora of fascinating ideas, each will blow your mind open. Fasten your futuristic seatbelt, as we break down exactly what his titles mean.

As a futurist, Brian is sought after by companies and organizations to generate predictions forecasting 10 years ahead based on current culture and industry trends. Brians predictions from a decade ago have turned out to be pretty spot on, proving that futurecasting can work. BDJ doesnt always stop at the 10 year mark - with some clients he looks as far into the future as imaginable, predicting dystopia and utopian scenarios.This helps companies to plot their specific course towards the future they want, and to prepare, disrupt, mitigate and recover from the futures that they don't want. For Brian, futurecasting is not about predicting the future, but rather about taking a pragmatic approach to determine a vision of the future that companies can then work to build.

As an author, BDJ gets to creatively prototype his ideas. He has written over 10 science fiction and science fact books and has created over 20 graphic novels. His most recent science fiction book is WAR: Wizards and Robots co-authored with will.i.am. Its a story of empowerment about a young female engineer who holds the power to save the world. However, most of Brians sci-fi graphic novels arent found on the shelves of bookstores, because they are privately owned by companies that hired BDJ to visually represent his futurecasting for employees. Lastly, he writes about robots and then uses those stories to enable kids to imagine, design and build their own robots.

BDJ and Wiil.I.am publish futuristic YA novel: Wizards and Robots

As a professor at Arizona State University Brian teaches and mentors students to become applied futurists. He is also the futurist in Residence at the Center for Science and the imagination. His last appointment is as the Director of the ASU Threatcasting Lab, where they work with organizations such as the United States Military and Secret Service to imagine a range of possible and potential threats to national and economic security. From there they can plan should undesired situations occur. When participating in threat casting the dress code is mandatory casual, flip flops encouraged, because BDJ and his team have learned that if you can see someone's toes its hard to get mad at that person while discussing touchy subjects.

As you can see with a small scratch of the surface, a whole new, futuristic, world is exposed. So how did Brian develop his career and what are his views on the future of work? Read on for his insights.

What did the pandemic exemplify in your work?

The pandemic is a destabilizing event. Destabilizing events are nothing new. We see them all the time. This could be a natural disaster, power outage or a regional conflict. The key to understanding destabilizing events is to understand two things:

1. What is the nature of the destabilizing event?

2. What is the magnitude of the destabilizing event?

With COVID - the nature of the event was a virus. And the magnitude was global.

These two factors made the pandemic a great accelerator. It's sped up changes that were already in progress and pointed out flaws that already existed. We saw this play out through global supply chains, the healthcare system, financial systems and how we use technology on a day-to-day basis.

I'm the futurist for the association of supply chain managers. As you can imagine, the supply chain had a really big pandemic. Supply chain went from something that was in the back office to something that was a conversation at the dinner table. We saw a lot of things that went wrong but we also saw a lot of things that went right.

During the pandemic the association did a survey of organizations looking at those who did futures planning and those who did not. One thing that they discovered was that the organizations that actively planned for their future generally had a 2 to 6 month business advantage because they took action before their competitors. This wasn't just for pandemic planning, many organizations hadn't done pandemic planning. But it was simply the ACT and the operationalization for thinking about and planning for the future that gave them head start.

The pandemic has shown all the necessity for planning for the future. Innovation comes not from predicting the future but for exploring a range of possible and potential futures to guard against strategic surprise.

Are there any interesting projects you are currently working on?

We just wrapped up a couple of multi-year projects that examine the future of information warfare and information disorder machines.A good place to start is to define the different elements of information disorder, mis-information, dis-information, and mal-information:

Mis-information - Spreading false information, but you dont know its false - most of the time this information stems from a small sliver of truth, say 10%, and becomes 10% truth and 90% misinformation. This information is usually not shared from a place of maliciousness, but simply not knowing its false.

Dis-information - When false information is knowingly shared to cause harm.

Mal-information - Leaking information that is designed to stay private and making it public with the intention to cause harm.

We examined information disorder paired with machine learning, algorithms, and artificial intelligence; and what that might mean for free speech and the future of the United States. Looking ten years out data will be gathered not only from places such as social media, but also from things such as smart cities, autonomous cars, and Internet of Things technologies. Not only will these places be gathering data, but they can also have the ability to message you - running the risk of sending dis-information or mis-information. Information disorder would then be able to be tailored on the fly to topics you are most passionate about that would incite or enrage you to take action. Oftentimes the goal of this type of attack isnt to get you to do one specific thing, but to create chaos and disorder - typically to get you to begin to question the validity of things such as government or businesses.

The best way to combat information disorder is to interrogate the information. Ask, who is saying this? And why are they saying this?

As a society we have to have a broader conversation around how to fact check and how to understand biases and inherent biases. In 2020 we began speaking more actively about this topic. It is a conversation that needs to happen more often to help people learn to pause before reacting and apply critical thinking to the messages that we are receiving. What is great is that we are beginning to design classes for schools to teach this next generation to think more constructively.

Graphic Novel, Invisible Force created by BDJ and the Threatcasting Lab at ASU

What do you believe the future of work will look like?

The question is not, what will the future of work look like? but it is what DO YOU want the future of work to look like? We are at an interesting moment in time, especially coming out of the pandemic where we have had a global destabilization when it comes to work. We are finding new modes of being and working and the future of work is localized and up to us. We dont have to do anything in a specific way as we come out of this destabilized event. Right now we have the ability to choose.

Everybody has the ability to shape their future. The first step is to realistically ask yourself, what is the future that I want? Once you have identified what your ideal future is, then you can start breaking it down to understand the agency that you have and most importantly identifying people you should be talking to and bringing together. To shape the future and create change it takes connecting with people - this can be in work and also in your community. Having a clear articulated picture of the future you want to create has incredible power and can draw people in to help you advance your vision. You have more control than you think.

Some things we can expect with the future of work does involve things such as automation and robotics. As we have learned from the pandemic, there are places where it is safer to not have humans doing specific tasks. If a robot or machine took your job, your job probably wasnt that great because it was turning YOU into a robot or machine. The industrial age turned human beings into machines. As we move into the future, the constellation of all the emerging technologies allows for us to be more human. We of course will have to remap the labor force and create wages for people to live comfortably.

People have asked me how they can future proof their career when it comes to the future work in the face of coming atomization. I tell them to be human! Thats the one thing the machines cant do. Everything we do is about humans. It begins with humans and ends with humans. There might be a lot of technology, businesses, processes and procedures in between but its always about people.

What does the future of technology look like?

Over the next 5 to 10 years a constellation of technologies will fundamentally remap the future of work. This includes artificial intelligence, smart cities, The Internet of Things, robotics, autonomy in land, sea and air as well as digital autonomy and increasing availability of computational intelligence and connectivity.

I have written about this and called it the coming age of Sentient Tools: technology that is aware, can think and is social with people. It will know us as individuals. Imagine working in a sentient office that is constantly using all of these technologies to make you safe, sustainable, productive but also is there to make your life better. Maybe even, your sentient elevator tells you a joke on Monday because you hate Mondays. The idea is that we keep human beings at the center of the technology tools we develop, not productivity or profit (although also important), but that ultimately everything we develop is to enhance the human experience. If we have the vision of what we want the future of technology to be then we can design ways in which technology can enhance and amplify humanity.

If you were to design the future or society what would it look like?

A society that keeps humans at the center. Everything we do is about humans. It begins with humans and ends with humans. There might be a lot of technology, businesses, processes and procedures in between but its always about people.

I always think back to Carl Sagan who used to tell people that our place in the universe is small and inconsequential. We arent even at the center of the universe, Earth is in the suburbs. We have to remember on this scale - that humans are not the central actor in this drama. We are bit players.

All we have is each other on this precious blue planet. It is important to also honor the world in which we live and realize that we are all interconnected.

Any final thoughts to add about the future?

The future isnt some fixed point on the horizon that we are all running towards helpless to take action. The future is built by people and organizations (run by people). The first step is to ask yourself or your organization:

From there you can start to take action.

The way that you change the future is you change the story that people tell themselves about the future that they will live in. If you can get yourself and others to see the future differently, then you can change the future. This is not just a nice thing to say, it is the truth of what I have seen over the last 25 years time and time again with people and organizations.

Remember that you need to be an active participant in your future. Never let someone else build your future for you...that never ends well.

Stay up to day on what BDJ is up to on Twitter @bdjfuturist

Continue reading here:
Influential Voices On The Future Of Work: Brian David Johnson, Futurist - Forbes

Posted in Futurist | Comments Off on Influential Voices On The Future Of Work: Brian David Johnson, Futurist – Forbes

Futurist Deborah Westphal Releases New Book, "Convergence: Technology, Business, and the Human-Centric Future" – PRNewswire

Posted: at 10:50 pm

SALT LAKE CITY, May 11, 2021 /PRNewswire/ -- Former Toffler Associates CEO and author, Deborah Westphal, launches her new book Convergence: Technology, Business, and the Human-Centric Future, and it's available today!

As a leader in future-focused strategy, Deborah Westphal leverages more than 30 years of experience in helpingthe world's most innovative business and government leaders to challenge biases, ignite ideas, and build connections. She delivers this rich insight with anempathetic and thought-provoking writing style to chart a path for readers. Throughout the book, personal stories and historical examples highlight convergences that span the globe, impacting everything from global supply chains to climate change, and reshaping the future of business, technology, and humanity everywhere.

Each day, we see deepening intersections of people, business, and technology. This is a historic inflection point that demands leaders rebalance the energy and focus we place on technology and humans within our organizations. Convergence alerts readers to signals of accelerating disruption and orients us to new mentalmodels, decision priorities, and the human-centric perspective we need to achieve a resilient global future.

Convergence is available for $26at all major booksellers and Amazon.com. For more information, please visit https://www.convergenceishere.com/.

About Deborah Westphal

Deborah Westphal's career spans more than 30 years, government agencies and Fortune 100 companies, and virtually every continent. In 1999, Alvin Toffler tapped her as one of the founding members of his eponymous consulting firm. A passionate humanist and life-long learner, she has guided leaders to challenge biases, ignite ideas, and build resilience for a secure future for organizations including Lockheed Martin, Northrop Grumman, Marriott, U.S. Air Force, Baxter International, Bayer, Heinz, Microsoft, Koppers, PPG, DARPA, National Security Agency (NSA), Loral Space Systems, NASA, Qwest, Verizon, and Westinghouse.

Contact: Kiki Keating[emailprotected] +1-603-858-2733

SOURCE Deborah Westphal

Original post:
Futurist Deborah Westphal Releases New Book, "Convergence: Technology, Business, and the Human-Centric Future" - PRNewswire

Posted in Futurist | Comments Off on Futurist Deborah Westphal Releases New Book, "Convergence: Technology, Business, and the Human-Centric Future" – PRNewswire

Unpacking Returnals UX design: Gameplay-first UI, retro-futuristic tech, and accessibility – PlayStation.Blog

Posted: at 10:50 pm

My name is Johannes Koski and Im the UI/UX Director of Returnal here at Housemarque. My role in the project has been both taking part in the design and overseeing and supporting the work done by the team. Ive had the privilege to work with a diverse multi-disciplinary group of amazing designers, artists, programmers, and audio specialists. Weve just launched a game that has been my ultimate dream project since I was a little kid, so Im super excited to be able to share something about our games UX!

The goal of a games UI is pretty straightforward: it guides the player and supports the game. In other words it gives the player all the necessary information and tools they need to understand and enjoy the games mechanics and at the same time it supports the games artistic core and storytelling with aesthetic means. In practice this unravels to hundreds of hours of planning, user interface design, concepting, usability studies, artistic choices, motion design, audio development, optimization, programming, player onboarding, and tutorial design to name a few areas.

Our core design principle is gameplay first. When designing the overall UX, one of our main goals was to remove all possible distractions from the second-to-second gameplay. We wanted to keep all the menus as clean and as minimal as possible. We even made the decision to not have a title screen or main menu at all and take the player always directly to the action.

We spent a considerable amount of time finessing all the HUD communications so that the player is always aware of critical gameplay information during intense bullet hell combat. We iterated a lot to find the perfect animation timings, intuitive color coding systems, and optimal information hierarchy to support various gameplay scenarios, etc.

The most crucial information needs to be communicated at the players immediate visual focus point in and near the reticle. Some critical guidance can be shown diegetically in and around the player character model and the actual game world. The content that is not essential for second-to-second survival can be shown in the periphery of the HUD.

Then we have the most important scenarios like near-death, low-health situations, where we throw everything we have at the players senses: HUD visor glass cracks and digital glitch animations, threatening vignettes, flashing warning icons, diegetic warning lights in players space suit, game world post-processing, health gauge color coding, player character animation, voice-over, VFX, emergency audio signals, and engaging haptic feedback.

Were especially happy how our unique 3D map and HUD minimap turned out. Theres a lot of verticality in our levels so a compass or a traditional 2D map wasnt enough. It was challenging to create a map system for randomly generated levels that was precise, looked good stylistically and wouldnt cause a performance hit. The map will be very helpful for both player guidance and planning combat flow.

Were using a wide variety of 3D Audio, DualSense wireless controller audio, and haptics to keep the player aware of their situation and surroundings even though their visual focus would be in combat and player survival. For example we implemented a rising charge-up UI sound that telegraphs the charge level of the alternative weapon fire, resolving in a distinct UI audio cue and haptics pulse once its fully charged. The haptics for this feature get prioritized in gameplay to give the player feedback on the most important combat cues.

Malignant items emit a heartbeat-like haptics pulse when nearby the player. This heightens the sense of risk and reward associated with these special items and helps in differentiating them from other pickups.

Parasites are another feature that received bespoke audio and haptics. Once you pick one of these up and it becomes attached to your suit, distinct haptic textures and audio cues of the parasite are used to remind the player they picked one up and that its active on the suit, potentially causing damage.

The hologram projections appearing while scanning a new item have been complimented by both haptics and sound effects, providing a granular sense of the scanner sweeping through the object as well as adding tactile weight to the interaction experience. Sending these sounds through the controller speaker as well made the whole scanning experience a lot more physical and real for the player.

For Returnals UI art direction, the main direction came from who Selene was, the company she worked for, and the technology she would have available to her. Strictly industrial and functional. This technology is also susceptible to damage and glitch errors because of the devices its displayed on: CRT monitors, tactile wrist computer displays, etc.

Theres a great correlation between the dated 70s aesthetic and good sci-fi horror. This could be because many of us grew up watching these movies and so they stay with us because of that sense of nostalgia. Our primary UI/HUD color is a haunting shade of teal that partly originates from the early monochrome cathode-ray tube computer monitors and tactical night-vision gear. The usage of this particular ghostly color also creates an eerie sense of looming horror.

(Concept art from Returnal, Mighty Canvas)

Looking at old consoles used in traditional industries, there is dedicated space for each component, most of the options are binary and there are no fancy gradients, transitions or effects. Its chunky and clunky, with little attention to visual flourishes.

We took this idea and limited the effects that we would use. So there is little to no directional motion. Everything flickers on and off. We chose to not create any layers. So no pop-ups over the screen UIs, as this felt too technically developed. The color palette was strict and the only effects and ambient animations are the ones we use to replicate the CRT aesthetic.

For the controls customization we wanted to make it as intuitive as possible and designed it so that the controller map is the very first thing you see when entering the options menu. From there we wanted to draw you in to trying out a different controller preset or create your own to fit your play style.

We put a lot of focus on making the remapping process easy to understand and use. Allowing you to quickly get an overview of where the actions are mapped, using a dynamic graphic on the right, we show where on the controller the action is currently mapped and if deciding to swap, showing which input you swap with.

While moving around actions and changing the layout of the DualSense wireless controller, we made sure you could easily see an overview of all of your changes directly from the remapping. A simple button press will bring up the full controller map so you can view your custom setup at any time.

This approach to previewing your changes was carried forward to use for other settings to make it easy to see your changes without having to return to gameplay for each change. When using a custom preset and you have rotated the whole controller for example, the preview on the right hand column will dynamically update to reflect that.If you are changing the deadzone on the right stick, we highlight the stick in the preview to make it clear which one you are changing.

Returnal has many different settings for controls, gameplay, audio, and video, and within these categories are features developed for accessibility. We worked from the ethos of these not being separated out to an accessibility category because there is such a wide range of players with different needs and these features can be used by everyone who wants them ensuring that we include rather than exclude players.

We also gave the player a larger range of choices for color blind mode. We added a slider for intensity so you can try it out and select what works for you. In addition we created three alternative color palettes for certain colors in the UI. The colors were selected based on their visibility and clarity for the three main color blind types: Deuteranopia, Protanopia, and Tritanopia. These options were added for players to try them out and use them if they found they helped increase clarity and visibility of HUD elements and text. We did the same for the collectible item beam colors, offering alternative options for players that wanted them.

We wanted to give you multiple options to play with when customizing the text. Adjusting the size, color, language, adding speaker names and background opacity were all added to make subtitles easier to read. All the changes can be previewed in the options menu, making their choice instantly clear to the player in the menu negating the need to exit and see the changes in-game.

Thanks for taking the time to learn about Returnals UI/UX art direction, and to all the players who have joined us on this journey. Returnal is out now on PS5.

Continue reading here:
Unpacking Returnals UX design: Gameplay-first UI, retro-futuristic tech, and accessibility - PlayStation.Blog

Posted in Futurist | Comments Off on Unpacking Returnals UX design: Gameplay-first UI, retro-futuristic tech, and accessibility – PlayStation.Blog

Toyota’s Futuristic Woven City Will Be Powered by Hydrogen – autoevolution

Posted: at 10:50 pm

The fact that Toyota started to build its own 175-acre city of the future its already yesterdays news. It is happening and its going to be a society of the future, fully automated, sustainable and interconnected using AI technology. But what we didnt know up until now was how theyre planning to power the entire ecosystem. Turns out theyre going to use hydrogen energy.

Toyota and ENEOS are going to test the hydrogen-based supply chain in and around Woven City, from the production phase to delivery and usage. The Japanese carmaker sees hydrogen as one of the cleanest energy sources available and tries to explore and implement the hydrogen and fuel cell technology as much as it can.

Woven City starts as a small-scale project, with a community of roughly 360 residents, but will eventually reach over 2,000 individuals, including Toyota employees. It will serve as a live-in laboratory for present and future Toyota technology and inventions.

The futuristic town will have three types of streets, each with its specific purpose: one for pedestrian use, another one for automated driving and the third one for pedestrians with personal mobility vehicles. The goal is to create a sustainable urban environment that promotes carbon neutrality in everyday mobility.

ENEOS is in fact a petroleum company that is now focusing on hydrogen production. The company operates 45 commercial hydrogen refueling stations in Japan and promotes a low-carbon use of energy.

Woven City will be located at the base of Mount Fiji, in Susono City, Shizuoka Prefecture. It was designed by Danish architect Bjarke Ingels, whose portfolio includes among others the LEGO House in Denmark, the two World Trade Center buildings in NYC, and Googles Mountain View and London HQ buildings.

See more here:
Toyota's Futuristic Woven City Will Be Powered by Hydrogen - autoevolution

Posted in Futurist | Comments Off on Toyota’s Futuristic Woven City Will Be Powered by Hydrogen – autoevolution

The Opulent, Futuristic Megamansion of Bill and Melinda Gates Could Be a Hard Sell – Mansion Global

Posted: at 10:50 pm

A trampoline room, an estimated $130 million market value and a size rivaling that of the White House are some of the unique features of the fortress-like Washington compound of the soon-to-be-divorced Bill and Melinda Gates.

But the suburban Seattle property, should it ever be up for grabs, could be a very tough sell.

Were all fascinated with this story for the obvious reasonsthe unfathomable wealth, these are both respected people on the world platform, said Ernie Carswell of Douglas Elliman, a Los Angeles-based agent with upward of 25 years of experience selling some of the citys most lavish and big-name properties.

They have an incredible home, but now, if it has to be sold, it's not going to be wham bam thank you maam, he said.

Dubbed Xanadu 2.0.but listed in property records as the more straight-laced Gates Residencethe ex-couples main home on the edge of Lake Washington near Seattle, is perhaps the jewel in the crown of a hefty property portfolio that has seen hundreds of millions of dollars invested across the U.S. in the form of beachfront mansions, equestrian estates and vast swaths of farmland, property records show.

I have a nice house, the Microsoft boss, whos worth an estimated $124 billion, said on Reddit in 2019. It includes a trampoline room which seems kind of over the top but my kids love using it to work off their excess energy. I am not sure how guilty I should feel about being in a great house.

Details of the home are scarce, but glimpses of what lies behind its walls have been revealed over the years, many in an account from a Microsoft intern who visited in 2007 and wrote about the experience in a blog post.

Going down Bills driveway is like arriving at Jurassic Park, the intern, Robert Smith, wrote, referring to the film. The driveway is long, windy, goes steeply down, and is just covered in plant life.

He also revealed the existence of a movie theater and a room that looked to be completely filled with couches and pillows.

We checked out his dock, his beach (with sand imported from Hawaii), hot tub and boat. Hes also got this area of his house where a stream runs down from under the house into Lake Washington, the intern wrote. We also saw the indoor/outdoor pool that has an underwater grate that allows you to swim between the two sections.

Such a degree of customization within a private residence doesnt make a home more valuable, though it does garner attention, according to Mr. Carswell.

It gets some great PR, a sound bite, Mr. Carswell said. I don't think it adds value, but it gives great recognition.

But the Gates trampoline room is probably going to become the next owners bowling alley, he said.

Spanning a reported 66,000 square feet, the compoundwhich property records indicate has a value of $130.8 milliondwarfs anything else on the market in Washington state currently.

A custom home built much larger and more lavishly than any property in the area can lead to difficulties when selling, Mansion Global previously reported.

The Chicago-area mansion of former NBA star Michael Jordan is a prime example.

Spanning 56,000 square feet, Mr. Jordans home is three times as large as the next largest mansion in the area and the house is loaded with custom amenities, including a regulation-size basketball court and a round infinity pool with a grassy island at its center.

The basketball legend first listed the mansion in 2012 for $29 million, and it remains on the market today asking $14.8 million.

In the case of the Gates house, the size isnt a detractor, but it's only going to appeal to a very limited number of buyers who come with their staff, Mr. Carswell said. You have the privilege and the responsibility of maintaining 60,000-70,000 square feet. Whos going to be dusting that?

Encompassing a more than five-acre waterfront parcel, the Gates Residencewhich came with $1.13 million property tax bill last year, public records showis in the upmarket Seattle suburb of Medina, where the most expensive home currently on the market is asking $22.5 million, according to listing records.

The likelihood of the residence ever hitting the market thoughand exact details of the split that was announced Monday have yet to be laid outis slim, according to local Medina agent Tere Foster, of Team Foster at Compass.

Firstly, they just have no need, said Ms. Foster, who is the listing agent on the aforementioned $22.5 million home. When I talk to clients in these categories they say we don't sell real estate, we acquire real estate.

So it would be unlikely. Are there buyers out here that can afford it? There are. There's a lot of local money and a lot of money outside of this market, she said. But its hard for me to imagine it would ever be sold.

And secondly, if the sprawling estate were ever going to change hands, its unlikely to be exchanged on the open market.

If the family wanted to sell, it would be marketed in a quiet way. They know all the people that could write the checks, Ms. Foster said.

The property is somewhat of a local landmark in Medina. I can tell you when we get people in from out of the country, buyers say, we want to live as close to the Gates compound as possible. You have people who move to Medina because Bill Gates lives there, she added. They're very good neighbors.

See the article here:
The Opulent, Futuristic Megamansion of Bill and Melinda Gates Could Be a Hard Sell - Mansion Global

Posted in Futurist | Comments Off on The Opulent, Futuristic Megamansion of Bill and Melinda Gates Could Be a Hard Sell – Mansion Global

Scientists Turned HIV Into a Life-Saving Gene Therapy – Futurism

Posted: at 10:50 pm

An experimental treatment gives kids with the genetic condition Severe Combined Immunodeficiency Syndrome (SCID), better known as bubble baby disease, a chance to go about life without the risk of constant infection and sickness.

SCID can be caused by a wide variety of genetic mutations that essentially disable a patients immune system. That makes everyday pathogens deadly to them, and kids with the condition constantly take antibiotics to try and manage the disease that otherwise tends to kill within a year or two of life, according to the Associated Press.

But those antibiotics are a short-term fix researchers at the University of California, Los Angeles decided instead to try to switch the immune system back on. In doing so, they discovered a seemingly counterintuitive trick: turning HIV, the virus that causes AIDS, into a delivery system that helped ferry a healthier version of the relevant genes and replace the mutated ones.

And it seems to work all 50 kids who received the experimental treatment are still alive and seem healthy years later, according to a study published Tuesday in the New England Journal of Medicine that followed up on the patients two and three years after treatment.

People ask us, is it a cure? Who knows long term, but at least up to three years, these children are doing well, Stephen Gottschalk of the St Jude Childrens Research Hospital, who didnt contribute to the new study but worked on similar projects in the past, told the AP. The immune function seems stable over time so I think it looks very, very encouraging.

Cure is often considered a loaded term, especially when talking about experimental treatments that havent seen mainstream use yet, but the limited study and the 50 tentative success stories offer a reason to suspect that gene-editing technology may be able to manage a notoriously dangerous disease down the road.

As a Futurism reader, we invite you join the Singularity Global Community, our parent companys forum to discuss futuristic science & technology with like-minded people from all over the world. Its free to join, sign up now!

See more here:
Scientists Turned HIV Into a Life-Saving Gene Therapy - Futurism

Posted in Futurist | Comments Off on Scientists Turned HIV Into a Life-Saving Gene Therapy – Futurism

Experts Shred Paper Claiming to Identify Mushrooms on Mars – Futurism

Posted: at 10:50 pm

Its the perfect headline: in a new paper, a group of scientists laid out evidence for why they think NASAs rovers and Mars orbiters have already collected photographic evidence of fungi on Mars. Could those bubble-shaped rocks really be puffball-like growths, basking in the radiation battering down on the desolate Martian surface?

Think again, experts say.

The conditions on Mars are so extreme that youre not going to see fungi or any kind of life growing at that sort of speed under conditions like coldness and low air pressure, Jonathan Clarke, president of Mars Society Australia,told the South China Morning Post. Life can barely survive, let alone thrive.

Clarke also took issue with the paper claiming that mushrooms were actually growing on Mars.

Its just like if you go to a beach and there are shells, he told the newspaper. If the wind blows, the sand moves and exposes more shells. But we wont say the shells are growing there, its just that they become visible.

The paper did have some fairly impressive credentialing, with authors listed from the Smithsonian Institute and George Mason University. But as it turns out, the lead author of the paper was Rhawn Gabriel Joseph, a fringe researcher known for dubious and unscientific claims about life on other planets.

Joseph has a lengthy track record of attempting to get his research published in reputable scientific journals. At one point, he even started his own renegade journal.

Joseph did break through and get a paper published in the journal Astrophysics & Space Science in November 2019, as Ryan points out but it was promptly retracted after finding the paper proffers insufficient critical assessment of the material presented and literature cited, and fails to provide a solid underpinning for the speculative statements made in the article which, in their view, invalidates the conclusions drawn.

In other words, the journal realized its mistake, and seemingly laughed him out of the room.

Josephs latest paper was published in the journal Advances in Microbiology, a journal headquartered in China thats been criticized for republishing existing articles, as Nature reported back in 2010.

And so here we are yet again,with the latest paper being shredded by the scientific community.

Claiming that mushrooms are sprouting all over Mars is an extraordinary claim that requires better evidence than an analysis of photographic morphology by a known crank who has claimed, on the basis of the same kind of analysis, that he has seen fields of skulls on Mars, University of Minnesota, Morris, developmental biologist Paul Myers told CNET.

In short, we have a mountain of evidence that Mars is extremely unhospitable to life as we know it on Earth. And photographic evidence is simply not nearly enough, experts say.

We have more than photos, records, instruments that tell us what these materials are made of, David Flannery, lecturer at the Queensland University of Technology who is a member of NASAs Mars 2020 mission science team, told SCMP. And we have models for the features we see around us.

Robots are sending back huge amounts of data, he added. We have plenty of information but its just that no one is interpreting the features that we see as something like fungi. Theres zero evidence for that.

This paper, which is really not credible, will be ignored by the scientific community, Flannery said.

Advances in Microbiologyhas remained quiet, failing to respond to Ryans requests for comment.

The journals managing editor Zoey Yang did tell SCMP that the paper was accepted with revisions as we received four review results from different reviewers after peer review. They all suggest that we accept it after some revisions.

Its an admittedly enjoyable daydream: the prospect of mushrooms growing on Mars would be a tremendous breakthrough in our understanding of our Solar System and humanitys place in the universe.

But without backing up such claims with extensive evidence and compelling support from academic peers the findings should be treated with a grain of salt.

READ MORE: No, NASA photos are not evidence of fungus growing on Mars, sorry [CNET]

More on Joseph: Extremely Dubious Scientist Believes Theres Mushrooms and Lichen on Mars

As a Futurism reader, we invite you join the Singularity Global Community, our parent companys forum to discuss futuristic science & technology with like-minded people from all over the world. Its free to join, sign up now!

Originally posted here:
Experts Shred Paper Claiming to Identify Mushrooms on Mars - Futurism

Posted in Futurist | Comments Off on Experts Shred Paper Claiming to Identify Mushrooms on Mars – Futurism

Page 946«..1020..945946947948..960970..»